Effectiveness of directly observed therapy (DOT) for tuberculosis: A review of multinational experience reported in 1990-2000

Medicine

Volumn 81, Issue 3, 2002, Pages 179-193

  Hill, A Ross ^a   Manikal, Vivek M ^a   Riska, Paul F ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM CULTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; TUBERCULOSIS;

DIRECTLY OBSERVED THERAPY; DRUG RESISTANCE, MICROBIAL; HIV INFECTIONS; PATIENT COMPLIANCE; TUBERCULOSIS;

EID: 0036247177     PISSN: 00257974     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005792-200205000-00002     Document Type: Article

References (110)

1. Short-course tuberculosis chemotherapy in rural Somalia
2. A prospective study of tuberculosis and human immunodeficiency virus infection: Clinical manifestations and factors associated with survival
3. Effectiveness of supervised, intermittent therapy for tuberculosis in HIV-infected patients
4. Control of tuberculosis - The law and the public's health
5. DOT or not? Direct observation of anti-tuberculosis treatment and patient outcomes, Kerala State, India
6. Directly observed therapy and treatment completion for tuberculosis in the United States: Is universal supervised therapy necessary?
7. Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis
8. Directly observed therapy for tuberculosis given twice weekly in the workplace in urban South Africa
9. Case holding
10. A controlled trial of six months chemotherapy in pulmonary tuberculosis
11. Resurgent tuberculosis in New York City
12. Noncompliance with directly observed therapy for tuberculosis
13. A cost-effectiveness analysis of directly observed therapy vs self-administered therapy for treatment of tuberculosis
14. Evaluation of a directly observed six month fully intermittent treatment regimen for tuberculosis in patients suspected of poor compliance
15. Two-year follow-up of directly observed intermittent regimens for smear-positive pulmonary tuberculosis in China
16. Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection
17. 4-, 5- and 6-month regimens containing isoniazid, rifampicin, pyrazinamide and streptomycin for treatment of pulmonary tuberculosis tinder program conditions in Hong Kong
18. Directly observed therapy for treatment completion of pulmonary tuberculosis
19. Modeling the epidemiology and economics of directly observed therapy in Baltimore
20. Results of directly observed short-course chemotherapy in 112,842 Chinese patients with smear-positive tuberculosis
21. Control of tuberculosis by community health workers in Bangladesh
22. A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis
23. USPHS tuberculosis short-course chemotherapy trial 21: Effectiveness, toxicity, and acceptability
24. First-line tuberculosis therapy and drug-resistant Mycobacterium tuberculosis in prisons
25. Relapse and mortality among HIV-infected and uninfected patients with tuberculosis successfully treated with twice weekly directly observed therapy in rural South Africa
26. Short-course chemotherapy for pulmonary tuberculosis with a rifampicin-isoniazid-pyrazinamide combination tablet
27. Critical assessment of smear-positive pulmonary tuberculosis patients after chemotherapy under the district tuberculosis programme
28. Twice-weekly, directly observed treatment for HIV-infected and uninfected tuberculosis patients: Cohort study in rural South Africa
29. Directly observed treatment for tuberculosis
30. Global burden of tuberculosis: Estimated incidence, prevalence, and mortality by country
31. Failure of drug penetration and acquisition of drug resistance in chronic tuberculous empyema
32. Directly observed therapy for tuberculosis: The Harlem Hospital experience
33. Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis
34. Standard short-course chemotherapy for drug-resistant tuberculosis: Treatment outcome in 6 countries
35. Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: A randomised trial
36. Comparison of cost effectiveness of directly observed treatment (DOT) and conventionally delivered treatment for tuberculosis: Experience from rural South Africa
37. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946-1886, with relevant subsequent publications
38. Tuberculosis in New York City - Turning the tide
39. Directly observed therapy in New York City: History, implementation, results, and challenges
40. Chemotherapy of tuberculosis under program conditions
41. Clinical consequences and transmissibility of drug-resistant tuberculosis in southern Mexico
42. What makes DOT work?
43. Disseminated tuberculosis in the acquired immuno-deficiency syndrome era
44. Tuberculosis
45. Evaluation of new anti-infective drugs for the treatment and prevention of tuberculosis
46. Outcome of first-line tuberculosis treatment in migrants from Vietnam
47. Directly observed treatment of tuberculosis: We can't afford not to try it
48. Efficacy of an unsupervised 8-month rifampicin-containing regimen for the treatment of pulmonary tuberculosis in HIV-infected adults
49. A prospective evaluation of antituberculosis therapy in patients with human immunodeficiency virus infection
50. Randomized controlled trial of directly observed treatment (DOT) for patients with pulmonary tuberculosis in Thailand
51. Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis
52. Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients
53. Delayed diagnosis of tuberculosis in patients with human immunodeficiency virus infection
54. Tuberculosis control in Bangladesh: Success of the DOTS strategy
55. Factors determining the outcome of treatment of adult smear-positive tuberculosis cases in The Gambia
56. The impact of HIV infection on recurrence of tuberculosis in South African gold miners
57. Can guardians supervise TB treatment as well as health workers? A study on adherence during the intensive phase
58. Tuberculosis treatment in Nepal: A rapid assessment of govermuent centers using different types of patient supervision
59. Successful supervised ambulatory management of tuberculosis treatment failures
60. Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis
61. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis
62. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis
63. Cost-effectiveness of directly observed versus self-administered therapy for tuberculosis
64. Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa
65. Human immunodeficiency virus and the outcome of treatment for new and recurrent pulmonary tuberculosis in African patients
66. Tuberculosis recurrence: Multivariate analysis of serum levels of tuberculosis drugs, human immunodefieiency virus status, and other risk factors
67. Directly observed intermittent short-course chemotherapy in the Kathmandu valley
68. Beyond directly observed therapy for tuberculosis
69. Directly observed therapy (DOT) for tuberculosis: Why, when, how and if?
70. The relationship between delayed or incomplete treatment and all-cause mortality in patients with tuberculosis
71. Non-adherence in tuberculosis treatment; Predictors and consequences in New York City
72. A model of the cost-effectiveness of directly observed therapy for treatment of tuberculosis
73. Pulmonary tuberculosis in HIV-infected patients in Zaire: A controlled trial of treatment for either 6 or 12 months
74. Observations on directly observed therapy for tuberculosis
75. Relapse of tuberculosis after treatment in human immunodeficiency virus-infected patients
76. The impact of comorbidity on mortality following in-hospital diagnosis of tuberculosis
77. Implementation of universal directly observed therapy at a New York City hospital and evaluation of an out-patient directly observed therapy program
78. Long-term effectiveness of intermittent therapy for tuberculosis: Final report of three Denver studies
79. Comprehensive tuberculosis control for patients at high risk for noncompliance
80. Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection
81. Dirctly observed therapy in an "inner city" hospital
82. DOT field worker fooled by a 9-year-old child who did not take her TB medications and relapsed with cavitary TB seven years later
83. Short-course chemotherapy studies conducted in Poland during the past decade
84. Cost-effectiveness analysis of directly observed therapy for patients with tuberculosis at low risk for treatment default
85. The effect of dosage cards on compliance with directly observed tuberculosis therapy in hospital
86. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: A cohort study in South African mineworkers
87. Relapse rates after short-course (6-month) treatment of tuberculosis in HIV-infected and uninfected persons
88. 10-Year assessment of treatment outcome among Cambodian refugees with sputum smear-positive tuberculosis in Khao-I-Dang, Thailand
89. When tuberculosis treatment fails: A social behavioral account of patient adherence
90. Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis
91. Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Interim report: No activity of isoniazid in the continuation phase
92. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment
93. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentene and isoniazid
94. Directly observed therapy and treatment adherence
95. Effectiveness of the direct observation component of DOTS for tuberculosis: A randomized controlled trial in Pakistan
96. DOT for patients with limited access to health care facilities in a hill district of Eastern Nepal
97. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis
98. Universal directly observed therapy
99. Treatment costs of directly observed therapy and traditional therapy for Mycobacterium tuberculosis: A comparative analysis
100. Directly observed therapy for tuberculosis in rural South Africa, 1991 through 1994
101. Efficacy of twice weekly treatment for tuberculosis given under direct observation in Africa
102. Revised international definitions in tuberculosis control
103. Tuberculosis control in the Caucasus: Successes and constraints in DOTS implementation
104. The impact of directly-observed treatment on the epidemiology of tuberculosis in Beijing
105. Randomized controlled trial of self-supervised and directly observed therapy of tuberculosis
106. A randomized controlled trial of lay health workers as direct observers for treatment of tuberculosis